Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 1999

View Archived Issues

Aviron: Q4 1998 highlights

NeoRx: Q4 1998 highlights

Viragen: Q2 1998 highlights

Agouron solves structure of key target for drugs to block angiogenesis

Hemosol successfully completes phase II trial of Hemolink in CABG patients

Uncompetitive NMDA antagonists show improved efficacy in Parkinson's disease models

Novel AD and metabolic syndrome targets as focus of Exelixis and P&U collaboration

Spotlight on agents for peripheral vascular disease

New anticancer agents from LG Chemical inhibit farnesyltransferase

Antithrombotic P2T antagonists in development at Astra

Muscarinic receptor modulators for psychotic disorders patented by Lilly

Bupropion more effective than nicotine patches in smoking cessation therapy

Merck discloses novel endothelin receptor antagonists

Chemokine receptor modulators from Merck & Co. described in recent patent literature

Cyclooxygenase-inhibitory indoles under study at Pfizer

Texas Biotechnology: Q4 and year-end 1998 results

Na+/Ca2+ exchange inhibitor provides effective neuroprotection in vitro

Findings from burn study demonstrate advantage of Apligraf + autograft versus autograft alone

Study suggests potential of MS-325 in blood pool imaging

diaDexus's first diagnostic product licensed to SmithKline Beecham unit

Pharmacia & Upjohn and Centocor to copromote Fragmin in unstable angina

Bio-Technology General receives added patent protection for novel anticoagulant

FDA approves controlled-release form of popular antidepressant

North American Vaccine adds new product to R&D pipeline; U.S. patent issues

Xenova reveals structure of P-gp-mediated MDR modulators, including clinical compound XR-9576

Microbial metabolite inhibits ICAM-1/LFA-1-mediated cell adhesion

Microbial fatty acid enhances endothelial cell fibrinolytic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...